NXTS Nexentis Technologies Inc.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.…
Industry Peers
Agricultural InputsKey Statistics
About Nexentis Technologies (NASDAQ: NXTS)
›
Nexentis Technologies (NASDAQ: NXTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Agricultural Inputs industry, part of the Basic Materials sector, and reports about 7 employees.
The shares were at 1.700 USD on 19 November 2026, down 98.6% over 52 weeks. Its 52-week range is 1.700 USD to 120.75 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.13M USD.
Nexentis Technologies reports return on equity of -25.0%.
It holds more cash than debt, a net cash position of 6.52M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.